SCHEMBL2522600

SCHEMBL2522600

CC(C)(C)NC(=O)c1ccc(C(=O)c2ccc(C(=O)NC(C)(C)C)cc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.53
HTT P42858 1/20 0.53
MAPT P10636 2/20 0.51
SRD5A2 P31213 1/20 0.50
KMT2A Q03164 1/20 0.48
SIRT2 Q8IXJ6 1/20 0.47
CYP2C9 P11712 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
EPHX1 P07099 1/20 0.47
HDAC1 Q13547 1/20 0.47
PRKAB2 O43741 1/20 0.46
PRKAG1 P54619 1/20 0.46
PRKAA2 P54646 1/20 0.46
PRKAA1 Q13131 1/20 0.46
PRKAG3 Q9UGI9 1/20 0.46
PRKAG2 Q9UGJ0 1/20 0.46
PRKAB1 Q9Y478 1/20 0.46
ALDH1A1 P00352 1/20 0.46
POLB P06746 1/20 0.46
JAK2 O60674 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17865779 0.93 LMNA (0.58) LMNAHTTMAPTSIRT2CYP2C9
SCHEMBL2264435 0.84 ALDH1A1 (0.61) LMNAHTTMAPTKMT2ASMN1; SMN2
SCHEMBL25753418 0.84 LMNA (0.51) LMNAHTTMAPTKMT2ASIRT2
SCHEMBL13762029 0.84 HDAC1 (0.67) LMNAHTTMAPTSRD5A2SMN1; SMN2
SCHEMBL162828 0.84 TSHR (0.54) LMNAHTTMAPTKMT2ASIRT2
SCHEMBL13701770 0.84 HDAC2 (0.59) LMNAHTTMAPTSMN1; SMN2EPHX1
SCHEMBL3716265 0.84 SRD5A2 (0.53) LMNAHTTSRD5A2CYP2C9SMN1; SMN2
SCHEMBL691761 0.83 KMT2A (0.56) LMNAHTTKMT2ACYP2C9HDAC1
SCHEMBL10577753 0.83 LMNA (0.50) LMNAHTTMAPTKMT2ASIRT2
SCHEMBL21016381 0.83 EPHX2 (0.51) LMNAHTTMAPTSIRT2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8034949-B2 Pyrrolidine compound and a process for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-11 US disclosed
US-20070167440-A1 Novel pyrrolidine compound and a process for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-07-19 US disclosed
EP-1748980-A1 PYRROLIDINE DERIVATIVES AS CB1-RECEPTOR ANTAGONISTS TANABE SEIYAKU CO., LTD. (JP) 2007-02-07 EP disclosed
WO-2005115977-A1 PYRROLIDINE DERIVATIVES AS CB1-RECEPTOR ANTAGONISTS TANABE SEIYAKU CO., LTD. (JP) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167440-A1 Novel pyrrolidine compound and a process for preparing the same CNR1, CNR2, OPRD1 LMNA 4698/4885HTT 1546/4885MAPT 4734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.